Инновационное развитие фармацевтической отрасли Китая: систематический обзор зарубежной научной литературы

Аннотация


Проведён систематический обзор зарубежной научной литературы, посвящённой инновационному развитию фармацевтической промышленности Китая. Рассмотрены ключевые факторы, влияющие на формирование и реализацию инновационного потенциала компаний, в том числе роль государственных субсидий, налоговых льгот, регуляторной политики и механизмов взаимодействия с научно-исследовательскими институтами. Отдельное внимание уделено проблемам фрагментации отрасли, региональным различиям в эффективности использования инновационных ресурсов и необходимости доработки правовой базы для защиты интеллектуальной собственности. Результаты исследования демонстрируют возрастающий интерес к разработке оригинальных препаратов, обусловленный усилением конкуренции на внутреннем рынке и стимулирующими мерами со стороны государства. Выводы и рекомендации могут быть полезны при разработке политики и практик управления инновационным развитием в отечественной фармацевтической отрасли.

Об авторах

Александр Александрович Резванов

Научно-исследовательский институт организации здравоохранения и медицинского менеджмента, Москва, Россия

Email: hi@aarezvanov.ru

Список литературы

  1. Scalera V. G., Perri A., Mudambi R. Managing innovation in emerging economies: organizational arrangements and resources of foreign MNEs in the Chinese pharmaceutical industry. Emerging Economies and Multinational Enterprises (Advances in International Management). 2015;28:201—233. doi: 10.1108/S1571-502720150000028011
  2. Hadengue M., de Marcellis-Warin N., Warin T. Reverse innovation and reverse technology transfer: from Made in China to discovered in China in the pharmaceutical sector. Management International. 2015;19(4):49—69. doi: 10.7202/1043076ar
  3. Sai Zhao, Yu Dongping, Wang Jingfei, Meng Zhengyang. Research on social network analysis method in cooperative innovation performance. Advances in Economics, Business and Management Research. 2020;146:79—84. doi: 10.2991/aeb-mr.k.200708.016
  4. Perri A., Scalera V. G., Mudambi R. What are the most promising conduits for foreign knowledge inflows? Innovation networks in the Chinese pharmaceutical industry. Industrial and Corporate Change. 2017;26(2):333—355. doi: 10.1093/icc/dtx004
  5. Zhang J. A., O'Kane C., Tao Bai. How do university-firm interactions affect firm innovation speed? The case of Chinese science-intensive SMEs. Research Policy. 2024;53(7):1—16. doi: 10.1016/j.respol.2024.105027
  6. Hongxia C., Hongtao Yang, Caihong X. Knowledge innovation performance evaluation in marine pharmaceutical enterprise in Zhejiang province China. J. Chem. Pharm. Res. 2014;6(5):284—289.
  7. Gao X. Y., Chen Y. F. Research on the path of improving the technological innovation ability of Chinese pharmaceutical industry based on technology. Pharmacol. Pharmacy. 2022;13(8):285—299. doi: 10.4236/pp.2022.138022
  8. Chen Y., He Q., Wang T. How labor costs affect innovation output in pharmaceutical companies: evidence from China. Inquiry. 2024;61:469580241246965. doi: 10.1177/00469580241246965
  9. Fu L., Zhang S., Wu F. The impact of compensation gap on corporate innovation: evidence from China’s pharmaceutical Industry. Int. J. Envir. Res. Public Health. 2022;19(3):1756. doi: 10.3390/ijerph19031756
  10. Zhu J., Tang Y., Wei Y. et al. Corporate financialization, financing constraints, and innovation efficiency — empirical evidence based on listed Chinese pharmaceutical companies. Front. Public Health. 2023;11:1085148. doi: 10.3389/fpubh.2023.1085148
  11. Wang S., Liu Q., Chen Y. Independent research and development, technology accumulation and innovation performance: evidence from China's pharmaceutical manufacturing industry. PLoS One. 2022;17(4):e0266768. doi: 10.1371/journal.pone.0266768
  12. Wu D., Wang S., Chang S. et al. Comparison of external R&D and internal R&D: Based on the perspective of S&T development of China's pharmaceutical manufacturing industry. PLoS One. 2022;17(6):e0270271. doi: 10.1371/journal.pone.0270271
  13. Lai H., Shi H., Zhou Y. Regional technology gap and innovation efficiency trap in Chinese pharmaceutical manufacturing industry. PLoS One. 2020;15(5):e0233093. doi: 10.1371/journal.pone.0233093
  14. Xia Y. The impact of R&D subsidies on firm innovation in different supervision situations: analysis from pharmaceutical companies in China. Technology Analysis & Strategic Management. 2022;36:1—18. doi: 10.1080/09537325.2022.2115882
  15. Lian Y., Leng J., Zhu Y. Government Subsidy, Research and Development Investment and Profitability Evidence from Pharmaceutical Manufacturing Enterprises. In: Proceedings of the 2022 International Conference on mathematical statistics and economic analysis. Zhengzhou; 2022:544—550. doi: 10.2991/978-94-6463-042-8_78
  16. Zejun Mei, Government Subsidies, Additional Deductions for R&D Expenditure and R&D Investment in the Pharmaceutical Industry. World Scientific Research Journal. 2020;6(5):175—179. doi: 10.6911/WSRJ.202005_6(5).0019
  17. Shi C. M., Zhao Y. Research exemption and pharmaceutical innovation: evidence from China. SSRN Electronic Journal. 2020:1—45. doi: 10.2139/ssrn.3766032
  18. Jiadong Pan, Gaobang Lin, Wen Xiao. The heterogeneity of innovation, government R&D support and enterprise innovation performance. Research in International Business and Finance. 2022;62:1—11. doi: 10.1016/j.ribaf.2022.101741
  19. Ni K. Does the crowd-out effect of R&D subsidies exist in the pharmaceutical industry? Evidence from Chinese companies. Modern Economy. 2020;11:645—656. doi: 10.4236/me.2020.113048
  20. Xia Yuntian, Fan Min, Zuo Xu, Hao Wenjing, Jia Yiwen. Government innovation subsidy, executives’ academic capital and innovation quality: evidence from pharmaceutical companies in China. Frontiers in Psychology. 2023;13:1—14. doi: 10.3389/fpsyg.2022.1092162
  21. Xu Jian, Wang Xiuhua, Liu Feng. Government subsidies, R&D investment and innovation performance: analysis from pharmaceutical sector in China. Technology Analysis and Strategic Management. 2021;33:535—553. doi: 10.1080/09537325.2020.1830055
  22. Deng P., Lu H., Hong J. et al. Government R&D subsidies, intellectual property rights protection and innovation. Chinese Management Studies. 2019;13(6):363—378. doi: 10.1108/CMS-02-2018-0422
  23. Zhen Cao. Research on evaluation of technological innovation capability of Chinese pharmaceutical manufacturing. Advances in Economics, Business and Management Research. 2021;178:110—113. doi: 10.2991/aebmr.k.210601.019
  24. Guan X., Chen L., Xia Q., Qi Z. Innovation efficiency of Chinese pharmaceutical manufacturing industry from the perspective of innovation ecosystem. Sustainability. 2022;14(20):12993. doi: 10.3390/su142012993
  25. Pengfei Ji. Analysis on the development of Chinese biopharmaceutical industry. Advances in Economics, Business and Management Research. 2022;212:106—112. doi: 10.2991/aeb-mr.k.220306.017
  26. Ni J., Zhao J., Ung C. O.L. et al. Obstacles and opportunities in Chinese pharmaceutical innovation. Global. Health. 2017;1:21. doi: 10.1186/s12992-017-0244-6
  27. Zhong S., Liang S., Zhong Y. et al. Measure on innovation efficiency of China’s pharmaceutical manufacturing industry. Front. Public Health. 2022;10:1024997. doi: 10.3389/fpubh.2022.1024997
  28. Yongfeng Qiu, Yongchao Yang, Renai Chen. Discussion on the choice of technology innovation strategy of Chinese pharmaceutical enterprises. Proceedings of Business and Economic Studies. 2019;2(4):28—31. doi: 10.26689/pbes.v2i4.829
  29. Song H., Zhang R. Analysis on innovation capability and influencing factors in Chinese pharmaceutical industry. Journal of Chemical and Pharmaceutical Research. 2014;6(1):389—393.
  30. Li Y., Shao Y. Study on the patent research and development in Chinese pharmaceutical industry. Journal of Simulation. 2017;5(2):117—120.
  31. Liu X., Song W. Necessity of implementing pharmaceutical patent linkage system in China. Public Policy and Administration Research. 2018;8(8):1—5.
  32. Ren S., Su:Open innovation and intellectual property strategy: the catch-up processes of two Chinese pharmaceutical firms. Technology Analysis & Strategic Management. 2015;27(10):1159—1175. doi: 10.1080/09537325.2015.1061117
  33. Fan Yang. Balancing pharmaceutical innovation and the Chinese Public interest: a comparative research of compulsory pharmaceutical licensing systems. Academic Journal of Humanities & Social Sciences. 2023;6(16):47—60. doi: 10.25236/AJHSS.2023.061608
  34. Xu G., Wang J. The current status of the biosimilars landscape in China. Biologicals. 2024;85:101744. doi: 10.1016/j.biologicals.2024.101744
  35. Chen X., Chen S., Wu Z. et al. The impact of centralized band purchasing of pharmaceuticals on innovation of Chinese pharmaceutical firms: an empirical study based on double difference models. Frontiers in Public Health. 2024;12:1406254. doi: 10.3389/fpubh.2024.1406254
  36. Wu J. Whether the public procurement policy can increase R&D innovation in the pharmaceutical enterprises. In: Proceedings of the 2023 3rd International Conference on Business Administration and Data Science. Dordrecht; 2023:51—60. doi: 10.2991/978-94-6463-326-9_6
  37. Yue C., Miraldo M. The effect of centralised procurement on pharmaceutical marketing and innovation: evidence from China. In: S&P Global Market Intelligence Research Paper Series. 2024:1—30. doi: 10.2139/ssrn.4755499
  38. Huang Ruomin, Feng Yukun, Cao Yumin. The impact of the volume-based procurement policy on organizational innovation investment: evidence from Chinese A-share pharmaceutical firms. Digitalization and Management Innovation II. 2023:311—323. doi: 10.3233/FAIA230743

Статистика

Просмотры

Аннотация - 189

PDF (Russian) - 71

Cited-By


PlumX

Dimensions


© АО "Шико", 2025

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Почтовый адрес

Адрес: 105064, г. Москва, ул. Воронцово Поле, д. 12, стр. 1

Email: redactor@remedium-journal.ru

Телефон: +7(495) 917-48-86

Редакция

Шерстнева Елена Владимировна
ОТВЕТСТВЕННЫЙ СЕКРЕТАРЬ
Национальный НИИ общественного здоровья имени Н.А. Семашко

105064, г. Москва, ул. Воронцово Поле, д. 12, стр. 1


E-mail: redactor@remedium-journal.ru

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах